TOPIC: SRS-necrosis
 

LEARNING OBJECTIVES:

• Analyze and discuss recommendations from evidence-based literature reviews. 
• Implement practical principles demonstrating key pragmatic takeaway pearls. 
• Discuss practical tips, interesting cases and workflow improvements in the practice of radiosurgery.

SPONSOR
Elekta

FACULTY AND DISCLOSURES:

Yazmin Odia, M.D., faculty for this educational event, has received trial support from Chimerix, BMS and Mimivax.  She is a part of the independent data monitoring board with Acutate.  She is a part of the data safety and monitoring board with GammaTile.  She is a consultant with Istari and PharPoint Research.  She is on the advisory board with Novocure.  She has indicated that the presentation or discussions will not include off-label or unapproved product usage.  All of the relevant financial relationships listed for this individual have been mitigated.  

Rupesh Kotecha, M.D., director for this educational event, has received research support from Medtronic Inc., Blue Earth Diagnostics Ltd., Novocure Inc., Exelixis, GT Medical Technologies, Astrazeneca, Viewray Inc., and Brainlab. He is a consultant for Accuray Inc., Elekta AB, Viewray Inc., Novocure Inc. Elsevier Inc., and Brainlab. He is also on the speakers bureau with Novocure Inc. and has indicated that the presentation(s) or discussion(s) will not include off-label or unapproved product usage.

Michael McDermott, M.D., director for this educational event, is a consultant with Deinde Medical, Stryker, Insightech, and Zap. He has indicated that the presentation(s) or discussion(s) will not include off-label or unapproved product usage. All of the relevant financial relationships listed for this/these individual(s) has/have been mitigated.

All of the relevant financial relationships listed for this/these individual(s) has/have been mitigated.

Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose with ineligible companies*

*Ineligible companies - Companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.